# Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

> **NCT04650204** · PHASE4 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 4 (actual)

## Conditions studied

- Intractable Epilepsy
- Malignant Glioma
- Seizure Disorder
- WHO Grade 2 Glioma
- WHO Grade 3 Glioma

## Interventions

- **DRUG:** Anticonvulsant Agent
- **DRUG:** Perampanel
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT04650204
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-04
- **Primary completion:** 2023-04-30
- **Final completion:** 2023-04-30
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** The funding sponsor, EISAI, sold the US rights to the medication and can no longer provide it to patients for the study.
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04650204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04650204, "Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04650204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*